Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
March 18, 2014
April 29, 2020
0cbdcef4-1b6b-45e5-8563-de1bb0a4e001
Related Documents
Clinical Pharmacology Considerations for Peptide Drug Products
Guidance DocumentDecember 14, 2023Center for Drug Evaluation and Research
Alcoholism: Developing Drugs for Treatment
Guidance DocumentFebruary 12, 2015Center for Drug Evaluation and Research
Data Integrity for In Vivo Bioavailability and Bioequivalence Studies
Guidance DocumentApril 3, 2024Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.